RL declares research grant to institution from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals; consulting fees from Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics; stock options from Sagimet Biosciences; and co-founder of LipoNexus Inc. EJL declares research grant to institution from 89bio inc, Akero Therapeutics, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CytoDyn, DSM, Eli Lilly and Company, Enyo Pharma, Galectin Therapeutics, Galmed Pharmaceuticals, Genentech, Genfit, Gilead Sciences Inc, GlaxoSmithKline, Hanmi Pharmaceuticals, Hightide Biopharma, Inventiva, Janssen Pharmaceuticals, Madrigal Pharmaceuticals, Merck & Co, NGM Biopharmaceuticals Inc, Northsea Therapeutics, Novartis, Novo Nordisk Inc, Pfizer, Poxel Co, Sagimet Biosciences, Terns , harmaceuticals, Viking Therapeutics, Zydus Pharmaceuticals (USA) Inc. RV declares research grant to institution from Galectin therapeutics, Takeda, Glaxosmithkline, Gilead; consulting fees from GlaxoSmithKline, INTERCEPT PHARMACEUTICALS, INC., Merck; participation on a Data Safety Monitoring Board or Advisory Board from Fortrea, Medpace, Madrigal, 89 Bio; Endpoint review committee from Jazz Pharmaceuticals, Aegios. JB declares consulting fees from Inventiva, Novo Nordisk, Siemens Healthcare; Payment for expert testimony from Echosens, Gilead Sciences Inc. EB declares consulting fees from MSD; payment or honoraria from MSD and Boehringer Ingenheim; Participation on a Data Safety Monitoring Board or Advisory Board from Eli Lilly and Company and Novo Nordisk. MY declares research grant to institution from Gilead Sciences, Inc. AJS declares research grant to institution from Eli Lilly and Company, Gilead Sciences (aka Gilead Foundation), Intercept Pharmaceuticals, Inc., Mallinckrodt LLC, Merck, Novo Nordisk, Perspectum, Pfizer Inc., Salix Pharmaceuticals, a division of Bausch Health US, LLC, Zydus; Royalties or licenses from Elsevier Publishing; Consulting fees from Akero, Amgen Inc., AstraZeneca, Boehringer Ingelheim, Genentech, Gilead Sciences (aka Gilead Foundation), GlaxoSmithKline, Histoindex, Intercept Pharmaceuticals, Inc., Inventiva, Merck, Pliant, Northsea, Novartis Pharma, Novo Nordisk, Path AI, Poxel, Regeneron Pharmaceuticals, Salix Pharmaceuticals, a division of Bausch Health US, LLC, Siemens, Boston Pharma, Surrozen, Takeda Pharmaceuticals America, Inc, Target Pharma Solutions, Terns, 89 Bio, Zydus Pharmaceuticals (USA) Inc.; Participation on a Data Safety Monitoring Board or Advisory Board/ Stock from Alnylam Pharmaceuticals, Bard Peripheral Vascular, Inc., Eli Lilly and Company, Madrigal, NGM biopharmaceuticals, Pfizer, Sequana; Srock or stock options from Durect, NorthSea, Rivus, Inversago, Tiziana. MLH, YT, BB, MCB, and AH are employees and shareholders of Eli Lilly and Company. Please refer to the accompanying ICMJE disclosure forms for further details.
PubMed
